FDA 483 - Xinfa Pharmaceutical Co., Ltd - April 05, 2016

An FDA inspection of Xinfa Pharmaceutical Co., Ltd. in Dongying, China, revealed significant concerns regarding manufacturing practices for dietary supplement ingredients. Observations included product residue on equipment deemed clean and released by Quality Control, as well as insufficient lighting for proper equipment inspection. These findings indicate potential deficiencies in quality control and facility maintenance.